ATLANTA, GA – – (Newsfile Corp. – September 29, 2020) – – Holzer & Holzer, LLC is investigating whether Myovant Sciences Ltd. (“Myovant” or the “Company”) (NYSE: MYOV) complied with federal securities laws. On September 29, 2020, the Company announced results of an additional secondary endpoint from the Phase 3 HERO study evaluating relugolix in men with advanced prostate cancer. The price of Myovant’s stock fell following the announcement. If you purchased shares of Myovant and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at email@example.com or Luke R. Kennedy, Esq. at firstname.lastname@example.org, or by toll-free telephone at (888) 508-6832 to discuss your legal rights.